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a  b  s  t  r  a  c  t
Mycobacterium neoaurum is a rare cause of bacteremia, and infection usually occurs in an
immunocompromised  host in the setting of an indwelling catheter. Prosthetic valve endo-
carditis  due to non-tuberculous mycobacteria typically carries a dismal prognosis; we report
a  case of M. neoaurum prosthetic valve endocarditis with favorable response to antimicrobial
therapy  without surgical intervention.eywords:
ycobacterium neoaurum
rosthetic  valve
ters  of rods with Gram positive characteristics and the acid
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ase  presentation
 30-year old Caucasian male presented to the emergency
epartment with shortness of breath and palpitations of two
eeks  duration associated with fever and chills. His past med-
cal  history was  signiﬁcant for multiple episodes of MRSA
methicillin resistant Staphylococcus aureus) endocarditis in the
etting  of intravenous drug use, for which he had undergone
ovine  mitral valve replacement a year prior. He admitted to
ontinued intravenous drug use. His vital signs on admission
ere  temperature of 101.4 ◦F, pulse rate of 106 per minute,
lood  pressure of 98/58 mm Hg and respiratory rate of 20 per
inute.  A grade 3/6 holosystolic murmur was  heard best at the
itral  area and radiated to the axilla. The lower extremities
ere  warm to touch. Distal pulses were intact and symmetric.
 detailed neurological exam was  unremarkable. Admission
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Este é um artigo Open Access sob a licençalaboratory tests showed a WBC  count of 16.8 K/mm3 with neu-
trophil  predominance (84%). Serum electrolytes, blood urea
nitrogen,  creatinine, creatine kinase (CK) and liver function
tests  were within the normal range. Chest X-ray showed
no  abnormality, and electrocardiogram showed normal sinus
rhythm  with mild left atrial enlargement.
Blood cultures were drawn and the patient was started on
empiric  antibiotic therapy with vancomycin, ceftriaxone and
rifampin  for provisional diagnosis of prosthetic valve endo-
carditis.  A transthoracic echocardiogram revealed extensive
vegetations on the prosthetic mitral valve with mild obstruc-
tion  to mitral inﬂow and a normal ejection fraction (Fig. 1).
The  Gram stain of the blood smear was reported as clus-SA.
, India.
fast  stain (Kinyoun) was  positive for acid-fast bacteria. Three
blood  culture bottles (aerobic) grew yellow shiny colonies
suggestive of Mycobacteria in 10 days. The organism was
 de CC BY-NC-ND
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Fig. 1 – Echocardiogram showing vegetations on the
prosthetic mitral valve with mild obstruction to mitral
inﬂow.
identiﬁed as Mycobacterium neoaurum using high-pressure liq-
uid chromatography. The patient was  treated with intravenous
tobramycin, oral azithromycin and oral moxiﬂoxacin based
on  susceptibility testing results. On day 10 of his hospital
stay  he developed severe abdominal pain. CT scan of the
abdomen  revealed a splenic and left renal infarct. Magnetic
Resonance Imaging (MRI) of brain revealed one centimeter
brain  abscess. Surgical intervention was  discouraged given his
ongoing drug use. The patient’s condition improved remark-
ably  within the next few days. His repeat blood cultures were
negative  on day 4 and his symptoms resolved. Although it
was  advised that he continue the same antimicrobial regi-
men  for an extended period of time, he was  unwilling to do
so.  He was  ﬁnally discharged on day 39 on a regimen of oral
azithromycin, ethambutol and moxiﬂoxacin. The patient did
not follow up with his physicians, and he was  readmitted a
year  later for prosthetic valve endocarditis due to coagulase
negative staphylococcal species. His AFB cultures drawn at
this  time were  negative. He responded to intravenous antibi-
otics  and surgical management was  once again not pursued
given  his ongoing intravenous drug use.
Discussion
Infective endocarditis due to mycobacterium species is
an  unusual but established clinical entity. Nontuberculous
mycobacteria (NTM) have been reported more  frequently as
a cause of infective endocarditis than Mycobacterium tuber-
culosis,  especially of prosthetic valves.1,2 The commonly
identiﬁed NTM species causing endocarditis have included the
following  rapidly growing mycobacteria: Mycobacterium fortu-
itum,  Mycobacterium abscessus, and Mycobacterium chelonae.2,3
NTM PVE has been described in both mechanical and bio-
logic  valvular prostheses. M.  neoaurum has been reported
rarely  as a cause of bloodstream infections in immuno-
compromised hosts, such as patients with malignancies or
transplant  recipients.4 M. neoaurum has also been implicated 1 4;1  8(2):235–237
in  pulmonary infections,5 meningoencephalitis,6 urinary tract
infection,7 and catheter related infections.4,8 van Duin et al.
reported  the ﬁrst case of PVE due to M. neoaurum with good out-
come in 2010.9 In our patient, the source of M.  neoaurum was
likely  contamination during illicit intravenous drug injection.
M.  neoaurum can be detected on routine aerobic blood cul-
tures  and is a rapidly growing organism on Lowenstein–Jensen
agar. The organism grows at temperatures between 25 and
35 ◦C, usually within ﬁve days. M. neoaurum colonies also
have  a characteristic yellowish-orange smooth appearance
that  is distinct from the colony characteristics of non-
chromogenic mycobacterium species. In many  of the reported
cases  of endocarditis due to NTM the blood cultures were
negative  and the identiﬁcation of the NTM was  done by
culturing  the removed prosthetic valve, or by histopath-
ology analysis in conjunction with molecular assays. The
advanced  methods for organism identiﬁcation include high-
pressure  liquid chromatography and genotypic methods like
sequencing of unique 16S rRNA.4 The 16S rRNA utilizes the
hypervariable nucleotide sequences that lend species-speciﬁc
variability within members of the same genus. Therefore, if
blood cultures are negative in a patient suspected of hav-
ing  PVE, deﬁnitive diagnosis can be made by removal of the
infected  prosthetic valve and performance of the aforemen-
tioned  studies. In an immunocompromised patient, however,
unexplained fever and symptoms of infection along with iso-
lation  of M.  neoaurum, particularly in multiple specimens,
should be considered highly suggestive of infection with this
organism.
Susceptibility  testing of rapidly growing mycobacteria
has several limitations: it is not standardized; results are
often  delayed well into empiric therapy, and most impor-
tantly  there is a lack of data linking clinical response
to in vitro test results. Presently, the minimum recom-
mendations for antibiotic susceptibility testing of rapidly
growing NTM include clarithromycin, amikacin, cefoxitin,
imipenem (the carbapenem preferred over meropenem and
ertapenem),  tobramycin, doxycycline, linezolid, ciproﬂoxacin,
and  sulfonamides.10 M.  neoaurum displays excellent suscep-
tibility  to ciproﬂoxacin while resistance to it is now widely
encountered amongst other rapidly growing NTM. A recent
study,  however, did demonstrate high resistance for M.  neoau-
rum  to clarithromycin.11 Combination antimicrobial therapy
including macrolides, ﬂuoroquinolones and aminoglycosides
is  a better therapeutic approach than monotherapy owing to
diagnostic delay in organism identiﬁcation and varying sus-
ceptibility  and resistance patterns for different mycobacteria
species. Endocarditis due to NTM, particularly involving the
prosthetic  valves, carries a dismal prognosis and requires
prolonged antibiotic therapy (ranging between 47 days and
187  days).3 Previously reported catheter related M.  neoaurum
infections required a minimum of three weeks of antimi-
crobial therapy, with recovery augmented by removal of the
infected  catheter.4 While prosthesis removal would have been
ideal,  the good therapeutic response in our patient could
be  due to the indolent nature and low pathogenicity of M.
neoaurum  and the excellent susceptibility proﬁle it displays
in  contrast to other NTM.12 This is further corroborated by
the  remarkable response to therapy for the patient reported
by  van Duin et al. and for majority of the patients who  had
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nfections of indwelling catheters due to M.  neoaurum.4,9 Since
here  is lack of considerable treatment experience for M.
eoaurum  endocarditis involving the prosthetic valves, we rec-
mmend several weeks of combination antimicrobial therapy
nd  removal of the infected prosthesis when possible.
In  conclusion, NTM PVE is a well-deﬁned clinical entity
hat  should be considered in patients with prosthetic valves
ho  present with symptoms of endocarditis with negative
lood  cultures. M. neoaurum is a rapidly growing NTM that can
ause  infective endocarditis in immunocompromised individ-
als.  NTM PVE due to M. neoaurum, in contrast to PVE due to
ther  NTM, may  be amenable to long term antibiotic ther-
py,  especially if combined with prosthesis removal. In the
bsence  of deﬁnitive regimens and substantial experience,
hysicians can rely on antibiotic susceptibility data and previ-
us  case reports to guide their antibiotic choice and duration of
herapy.  In general, however, endocarditis secondary to NTM,
articularly  involving the prosthetic valves, carries a poor
rognosis.
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